- German SPD leaders vote to start exploratory talks with conservatives
- Lebanon interior minister signs law for May election: statement
- 'Congratulations': EU launches next phase of Brexit but warns of tough
- Brazil's Temer to leave hospital, return to Brasilia
- Poland gives government key election role, opposition sounds alarm
- Prince Harry and Meghan Markle to wed on May 19, 2018
- Britain's Prince Harry and Meghan Markle to marry on May 19
- Finland lets stores sell stronger drinks, health chiefs complain
- Multi-summit Macron burns energy in hunt for results
- Erdogan says Turkey seeking to annul Trump decision on Jerusalem at U.
- Russian ex-minister Ulyukayev jailed for eight years over $2 million b
- Mexico's Senate passes divisive security law, paving way for final app
- U.S. says concerned about Myanmar's silence over where Reuters journal
- 'Congratulations': EU launches next phase of Brexit
- Novo Nordisk wins EU panel's backing for key diabetes drug
- Pakistani top court rejects bid to bar opposition leader Imran Khan
- Aclaris's drug to treat common skin growth gets FDA nod
- Catalan election to return hung parliament: poll
- Aclaris's drug to treat common growth on skin gets FDA nod
- FDA allows Alnylam to restart hemophilia treatment trials
FDA approves Mylan's biosimilar of Roche's cancer drug Herceptin
(Reuters) - The U.S. Food and Drug Administration on Friday approved Mylan NV’s biosimilar version of Roche’s blockbuster breast cancer treatment Herceptin.
The FDA said Mylan's Ogivri is the first biosimilar approved in the United States to treat breast cancer or stomach cancer and the second approved to treat cancer. (bit.ly/2zHuhul)
Mylan’s shares were up about 3 percent in late morning trading amid a drop in the broader market.
Herceptin is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years.
Annual sales of the Roche’s cancer medicines – Rituxan, Herceptin and Avastin – top $21 billion, or more than half of its pharmaceuticals business, but are under threat as their biosimilar versions get approval.
Biosmilars are a copycat of the original treatment and are just as effective, but cheaper.
The FDA in September approved Amgen Inc’s biosimilar version of Avastin.
Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila and Savio D'Souza
Our Standards:The Thomson Reuters Trust Principles.